EMA Withdrawn: Solymbic (adalimumab) — Amgen Europe B.V.

View source ↗

Summary

Solymbic (adalimumab) has been withdrawn from the market by Amgen Europe B.V.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Crohn Disease
• Hidradenitis Suppurativa
• Psoriasis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Ulcerative Colitis

Drugs mentioned

• Solymbic (adalimumab)

Snippet

Status: Withdrawn. Therapeutic area: Arthritis, Psoriatic;Spondylitis, Ankylosing;Crohn Disease;Colitis, Ulcerative;Hidradenitis Suppurativa;Psoriasis;Arthritis, Rheumatoid. MAH: Amgen Europe B.V.. Decision date: 22/06/2018